J Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION
|
|
- Osborne Harris
- 5 years ago
- Views:
Transcription
1 VOLUME 24 NUMBER 15 MAY JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Duration of Adjuvant Chemotherapy for Colon Cancer and Survival Among the Elderly Alfred I. Neugut, Matthew Matasar, Xiaoyan Wang, Russell McBride, Judith S. Jacobson, Wei-Yann Tsai, Victor R. Grann, and Dawn L. Hershman From the Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, and the Departments of Epidemiology and Biostatistics, Mailman School of Public Health, Columbia University; and the New York Presbyterian Hospital, New York, NY. Submitted October 6, 2005; accepted March 10, Supported by a K05 Award from the National Cancer Institute (NCI; Grant No. CA89155), a grant from the American Cancer Society (Grant No. RSGT CPHPS), and a Department of Defense Breast Cancer Center of Excellence Award (Grant No. BC043120) to A.I.N; an R25 fellowship from the NCI (Grant No. CA94061) to M.M.; a T32 fellowship from NCI (Grant No. CA09529) to R.M.; and an American Society of Clinical Oncology Career Development Award and a K07 Award from the NCI (Grant No. CA95597) to D.L.H. Authors disclosures of potential conflicts of interest and author contributions are found at the end of this article. Address reprint requests to Alfred I. Neugut, MD, PhD, Division of Medical Oncology, Columbia University Medical Center, 722 W 168th St, Rm 725, New York, NY 10032; ain1@ columbia.edu by American Society of Clinical Oncology X/06/ /$20.00 DOI: /JCO A B S T R A C T Purpose In randomized trials, patients with stage III colon cancer who received 6 months of fluorouracil (FU)-based adjuvant chemotherapy had better survival than patients who did not. However, little is known about the predictors of, or the survival associated with, duration of chemotherapy in the community. Patients and Methods The linked Surveillance, Epidemiology, and End Results-Medicare database was used to identify individuals 65 years of age diagnosed with stage III colon cancer between 1995 and We used logistic and Cox proportional hazards regression models to analyze factors associated with early discontinuation of FU-based chemotherapy among these elderly colon cancer patients. Results Among 1,722 patients who received 1 to 7 months of FU-based chemotherapy, older age, being unmarried, and having comorbid conditions were associated with receiving less than 5 months of treatment. Among the 1,579 patients who survived 8 months, the 1,091 (69.1%) who received 5 to 7 months of treatment had lower overall (hazard ratio [HR], 0.59; 95%, CI 0.49 to 0.71) and colon cancer-specific (HR, 0.53; 95% CI, 0.43 to 0.66) mortality than the 488 (30.9%) who received 1 to 4 months of treatment. Conclusion More than 30% of elderly patients who initiated FU-based chemotherapy for stage III colon cancer and survived for at least 8 months discontinued treatment early. Mortality rates among such patients were nearly twice as high as among patients who completed 5 to 7 months of treatment. If the association we observed between duration of treatment and survival is confirmed, additional investigation is warranted to determine whether dose-intensity, cumulative dose, or other factors related to receipt of full adjuvant treatment are responsible. J Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION The use of adjuvant chemotherapy for localized breast cancer and colon cancer has been among the most important advances in medical oncology in terms of lives saved. 1-3 For breast cancer adjuvant chemotherapy, studies have shown that patients who receive dose-intense treatment fare better than those who do not. Bonadonna et al 4 demonstrated that the benefit of adjuvant chemotherapy was limited to patients who received 85% of the optimal dose, and that patients who received less treatment fared no better than those who received none. Largescale clinical trials have established that dose reductions, delays, or interruptions of chemotherapy for breast cancer can reduce its benefits. 5-7 However, as many as 50% of patients either fail to initiate or do not receive all their recommended cycles of chemotherapy in a timely fashion. 8,9 Our group recently found that among women with breast cancer who initiated adjuvant chemotherapy, 28% terminated treatment early and that the earlier they terminated treatment, the higher was their mortality hazard ratio compared to those who completed treatment. 10 Colon cancer is a significant public health problem in the United States. Among individuals age older than 75 years, it is the most frequently diagnosed malignancy 11,12 and the second leading cause of cancer death In the 1980s, the combination of fluorouracil (FU) with biochemically modulating agents, such as levamisole or folinic acid, was shown to extend survival for locally advanced stage III colon cancer. 16 A meta-analysis confirmed the benefits of such chemotherapy for the elderly. 17 Even before the North Central Cancer 2368
2 Adjuvant CT for Colon Cancer in the Elderly Treatment Group National Cancer Institute of Canada trial reported that patients treated for 12 months do not fare better than those who received 6 months of adjuvant chemotherapy, 6 months of treatment was becoming accepted as the standard of care. 3 No consensus has emerged at this time regarding the optimal dose-intensity of bolus FU. We, and others, have found that elderly patients benefit as much from FU-based adjuvant chemotherapy as do younger nodepositive colon cancer patients treated during clinical trials, but that 50% or more of elderly patients with stage III colon cancer do not receive treatment Since 1995, the standard of care for the adjuvant treatment of node-positive colon cancer has been FU-based chemotherapy administered for about 6 months, 16,21 but no studies have explored the prevalence and effects of early termination. Therefore, we have analyzed the frequency, determinants, and outcomes of early discontinuation of FU-based chemotherapy in a nationwide sample of elderly colon cancer patients. PATIENTS AND METHODS Data Source Our analysis used a database developed by Potosky et al 22 in 1993, in which the files of patients with cancer from the National Cancer Institute s Surveillance, Epidemiology, and End Results (SEER) cancer registry were linked with their Medicare claims files. The SEER database provides information on tumor histology, location, stage of disease, and individual demographics, as well as primary surgical and radiation treatment and survival data for cancers occurring in a representative sample (approximately 14% during the period of our study) of the US population. The Medicare database, maintained by the Health Care Finance Administration (HCFA) complements the SEER data with extensive diagnostic, treatment, and cost information. Sample Selection We identified all individuals in the linked SEER-Medicare database diagnosed with primary colon cancer in the years 1995 to 1999 (n 42,249), at age 65 years (n 37,028), and in American Joint Cancer Committee stage III (n 7975). We excluded 2,894 patients who were enrolled in a health maintenance organization (HMO) at any point from 12 months before to 8 months after initiation of FU chemotherapy or, for patients who did not receive FU, after surgery (HCFA does not collect claims data from risk-based HMOs) and/or were not covered by Medicare Parts A and B at any point during that time period. Of the remaining 5,081 patients, we also excluded 483 patients who did not have positive regional nodes confirmed on pathology and surgical resection of the tumor. We also excluded 57 who received chemotherapy that did not include FU and 808 who received more than 7 months of treatment because they could not be distinguished from patients intended to receive longer (eg, 12 month) regimens. The remaining patients were categorized by duration of treatment, age group at diagnosis, year of diagnosis, race/ethnicity, sex, marital status, number of positive lymph nodes, tumor grade (well/moderately differentiated or poorly differentiated), comorbidity score, residence (metropolitan or nonmetropolitan area), the type of hospital in which they were diagnosed (teaching or nonteaching), and the socioeconomic status (SES) of their census tract/zip code. We obtained data on age, race, sex, marital status, surgery, stage, tumor grade, lymph nodes, type of hospital, and area of residence from the SEER database, and data on comorbid conditions and treatment from Medicare. Treatment With FU Using HCFA codes and the Common Procedure Coding System (HCPCS code), we identified patients who had received FU (level II HCPCS J9190) either in a physician s office or at an outpatient department within a hospital. Those who began FU within 120 days of their cancer diagnosis were classified as receiving adjuvant FU treatment. For patients who did not receive FU, we assessed whether level II HCPCS codes or International Classification of Diseases (9th revision, clinical modification [ICD9-CM] diagnostic codes from their physician claims files showed evidence of other chemotherapy delivery. Treatment duration was measured as the number of months between the first and last FU chemotherapy claims in patients who received no more than 7 months of treatment. The number of doses and the route of chemotherapy administration were not recorded. The validity of SEER-Medicare claims data for chemotherapy use in general, and FU use in particular, has been described previously. 23,24 SES We generated an aggregate SES score from a hierarchy of income data from the 2000 census, following the method described by Bach et al. 25 Patients were ranked ona1to5scale, where 1 was the lowest value, based on a formula incorporating as many of the following as were available: median income in the census tract of residence, median income in the zip code of residence, census tract per capita income, and zip code per capita income; patients for whom all of these values were missing were assigned to the lowest SES category. Comorbid Disease To assess the prevalence of comorbid disease in our cohort, we used the Klabunde adaptation of the Charlson comorbidity index Medicare inpatient and outpatient claims were searched for ICD9-CM diagnostic codes indicating a history of myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, connective tissue disease, peptic ulcer disease, mild to severe liver disease, diabetes with/without end organ damage, hemiplegia, moderate or severe renal disease, or AIDS in the Medicare files from 12 months before to 1 month after their diagnosis of cancer. Each condition was weighted, and patients were assigned a score based on the Klabunde-Charlson index. 28 Survival Survival time was calculated as the number of months from the cancer diagnosis date to the Medicare date of death. Those surviving past December 30, 2000, were classified as censored (alive at the end of follow-up) and contributed the time interval from their diagnosis date to the end of follow-up to the survival analysis. We used the SEER determination of cause of death from colon cancer using ICD8, ICD9, and ICD10. SEER updates these files annually. Statistical Analysis We used 2 tests to compare patients who received 1 to 4 months and 5 to 7 months of treatment, with respect to the variables listed above. We then developed proportional hazards regression models to analyze the mortality associated with each incremental month of treatment, compared with no treatment. Among patients who received 1 to 7 months of treatment, we used logistic regression to estimate odds ratios (ORs) and 95% CIs for factors associated with receiving 5 to 7 versus 1 to 4 months of FU chemotherapy and with dying in the first 8 months given the baseline risk factors. We then excluded patients who died within the first 8 months from our analysis and developed Cox proportional hazards models to compare colon cancer specific and overall mortality rates among patients who received 5 to 7 months of treatment with those for patients treated for 1 to 4 months, controlling for the baseline risk factors. Propensity scoring is a technique used to measure the likelihood that a patient will be treated solely based on that patient s independent predictors of treatment. 29 We used the coefficients for the predictors of 5 to 7 months (v 1to 4 months) of treatment to assign to each patient a composite propensity score that could be used in lieu of the covariates included in the multivariable proportional hazards analysis. We added any covariates that remained statistically significant to the propensity score-adjusted model. The hazard ratio for the association of treatment duration with mortality derived from the propensity score adjusted model did not differ appreciably from that derived from the multivariate analysis. We decided to present the multivariable analysis results because they include information about the association of mortality with the covariates. Unadjusted Kaplan-Meier analyses were used to compare the two treatment groups with respect to colon cancer specific and overall survival
3 Neugut et al RESULTS Baseline Characteristics of the Analysis Group Of the 3,733 patients in the SEER-Medicare database who received a pathologically confirmed diagnosis of stage III colon cancer and were not members of an HMO during 1995 to 1999, most were non-hispanic whites (86.5%), resided in a metropolitan area (87.6%), and were treated in nonteaching hospitals (79.1%; Table 1). In a preliminary analysis of month-by-month duration of treatment, we found that the mortality rates of those who received 1, 2, 3, or 4 months of FU-based chemotherapy were similar to the mortality rates of those who received no treatment and markedly higher than Characteristic Table 1. Demographic and Clinical Characteristics of Patients by Duration of FU Chemotherapy Months of Chemotherapy No. of Patients % No. of Patients % No. of Patients % Total No. of Patients % Total 2, , , Age at diagnosis, years Year of diagnosis Race/ethnicity.04 White Black Other/unknown Sex.1 Male Female Marital status.0003 Unmarried Married Other/unknown Grade.8 Well/moderately differentiated Poorly differentiated Unknown Klabunde-Charlson comorbidity score Positive lymph nodes Residence.001 Metropolitan area Nonmetropolitan area Hospital where diagnosed.5 Nonteaching Teaching Other/unknown Socioeconomic status, quintile.002 Lowest Second Third Fourth Highest Abbreviation: FU, fluorouracil. Values are based on 2 tests comparing patients who received 1-4 months of FU with those who received 5-7 months of FU. P 2370 JOURNAL OF CLINICAL ONCOLOGY
4 Adjuvant CT for Colon Cancer in the Elderly those of patients who received 5 to 7 months of treatment (roughly consistent with the 1995 recommendation of 6 months of treatment 3 ; Fig 1). In our subsequent analyses, therefore, we compared patients who received 1 to 4 months with patients who received 5 to 7 months of FU treatment. Predictors of Receiving 5 to 7 Months of FU Chemotherapy Table 2 lists the results of the logistic regression analysis of determinants of duration of treatment. In our multivariable model, treatment for 5 to 7 months was associated with younger age, more recent year of diagnosis, being married, having a tumor of well/moderately differentiated grade, and having no comorbid conditions. Early Mortality Some patients who discontinued treatment early may have done so because of deteriorating performance status and prognosis. Moreover, patients who died within 8 months after diagnosis did not have the opportunity to benefit from FU chemotherapy even if they initiated it. Table 3 summarizes the results of the logistic regression analysis of mortality within 8 months after diagnosis among patients who received 1 to 7 months of FU treatment. The predictors of early mortality were older age, earlier year of diagnosis, having more than one positive lymph node, having a tumor of poorly differentiated grade, and having a comorbidity score of more than 1. Mortality After 8 Months Table 4 lists the results of the Cox proportional hazards regression analyses of factors associated with disease-specific and overall mortality among patients who had the opportunity to benefit from FU treatment. Among the 488 patients who received 1 to 4 months of therapy and survived 8 months, 154 were recorded as subsequently dying as a result of colon cancer, whereas 55 died as a result of other causes. For the 1,091 patients treated with 5 to 7 months of chemotherapy, 188 died as a result of colon cancer, whereas 79 died as a result of other causes. Disease-specific mortality among the 1,091 patients who received 5 to 7 months of treatment was half that of the 488 patients treated for 1 to 4 months (OR, 0.53; 95% CI, 0.43 to 0.66). Overall mortality was approximately 44% lower among patients who Table 2. Association of Demographic and Clinical Characteristics With 5-7 Months of Treatment Among All Patients Initiating FU Characteristic Odds Ratio 95% CI Age at diagnosis, years Referent to to to 0.52 Year of diagnosis Referent to to to to 3.31 Race White 1.00 Referent Black to 2.48 Sex Male 1.00 Referent Female to 1.17 Marital status Unmarried 1.00 Referent Married to 1.68 Positive lymph nodes Referent to 1.18 Grade Well/moderately differentiated 1.00 Referent Poorly differentiated to 0.96 Klabunde-Charlson comorbidity score Referent to to 0.84 Residence Metropolitan area 1.00 Referent Nonmetropolitan area to 1.65 Hospital where diagnosed Nonteaching 1.00 Referent Teaching to 1.40 Socioeconomic status, quintile Lowest 1.00 Referent Second to 1.78 Third to 1.36 Fourth to 1.25 Highest to 1.17 Abbreviation: FU, fluorouracil. Based on a multiple logistic regression model in which each variable was adjusted for all others. Estimates for other race or unknown variables in the model are not reported because of small numbers. were treated longer (OR, 0.59; 95% CI, 0.49 to 0.71). More than one positive lymph node, a tumor of poorly differentiated grade, and a higher comorbidity score were also associated with worse diseasespecific and overall mortality. Fig 1. Proportional hazards ratios for mortality given each incremental month of treatment, compared with no treatment, among 1,579 patients who survived more than 8 months after diagnosis and received 1 to 7 months of adjuvant fluorouracil (FU) chemotherapy. Survival In unadjusted Kaplan-Meier survival analyses, both colon cancer specific (Fig 2A) and overall survival (Fig 2B) were better among those stage III colon cancer patients receiving 5 to 7 months of FU therapy than among those receiving 1 to 4 months of therapy
5 Neugut et al Table 3. Predictors of 8 Months Survival Among Patients Receiving 1-7 Months of FU Predictor Odds Ratio 95% CI Age at diagnosis, years Referent to to to 3.40 Year of diagnosis Referent to to to to 0.77 Race White 1.00 Referent Black to 1.79 Sex Male 1.00 Referent Female to 1.17 Marital status Unmarried 1.00 Referent Married to 1.05 Positive lymph nodes Referent to 2.20 Grade Well/moderately differentiated 1.00 Referent Poorly differentiated to 3.88 Klabunde-Charlson comorbidity score Referent to to 2.84 Residence Metropolitan area 1.00 Referent Nonmetropolitan area to 1.99 Hospital where diagnosed Nonteaching 1.00 Referent Teaching to 2.59 Socioeconomic status, quintile Lowest 1.00 Referent Second to 1.09 Third to 1.65 Fourth to 1.73 Highest to 1.64 Abbreviation: FU, fluorouracil. Based on a multiple logistic regression model in which each variable was adjusted for all others. DISCUSSION In a population-based sample of colon cancer patients older than 65 years who survived at least 8 months after diagnosis and initiated FU-based chemotherapy, more than 30% discontinued their treatment early. Factors associated with early discontinuation included increasing age, white race, worse tumor grade, and having a comorbidity score higher than 1. Mortality among patients who discontinued treatment early was nearly twice as high as among those who did not. In a prior study by our group, 19 mortality among patients who received any adjuvant FU was 37% lower than among those who received surgery alone. Our current analysis suggests that the benefit we observed previously was driven by patients who completed 6 months of treatment, consistent with the results of randomized trials. 3 Some prior studies have found that black patients are less likely than white patients to initiate adjuvant therapy in the treatment of both breast cancer 9 and colorectal cancer. 18,19 Our group has also observed an association between race and early termination of breast cancer treatment. 10 However, other investigators have found inconsistent associations between treatment adherence and race or SES. 30,31 Although there was a trend toward more early discontinuation of chemotherapy among black patients (OR, 1.56; 95% CI, 0.98 to 2.48), race was not significantly associated with mortality. The literature on the quality of colon cancer treatment in relation to survival is sparse. One study of treatment compliance in 139 patients who were to receive 12 cycles of adjuvant chemotherapy for stage III colon cancer found that, among patients who received six or more cycles, the recurrence rate was 7%; among those who received five or fewer cycles, the recurrence rate was 36%, suggesting that survival was associated with the cumulative dose of FU. 32 In randomized clinical trials, in which adherence is known to be higher than in the community, 15% to 30% of patients also fail to complete all of the prescribed cycles of FU-based chemotherapy ; dose reductions occurred frequently after the first two cycles. 34 Six months of chemotherapy appears to be as effective as 12 months of therapy. 3 In a recent trial, 3 months of continuous-infusion FU appeared to be as effective as 6 months of bolus FU 36 ; however, the participants included both patients with stage II disease and patients who were treated with radiation therapy for rectal cancer. No other studies have analyzed the effects of limited bolus FU treatment with mortality. Our findings in this population-based sample of patients with colon cancer are strikingly similar to our findings and those of others among patients with breast cancer. 4,10,37 We found that, like many breast cancer patients, many colon cancer patients failed to complete their adjuvant chemotherapy. Others have reported poor adherence to chemotherapy for lymphoma 38 and poor adherence to hormonal therapy for breast cancer. 39,40 Although we also found that early discontinuation of treatment was associated with poor survival, we cannot assume that that association is causal. Some patients may be at high risk for adverse outcomes because of the same factors that cause them to discontinue treatment: poor physical condition, performance status, psychological outlook, or health behaviors. In addition, some patients may have discontinued treatment early in response to toxicity. However, FU toxicity is unlikely to account for much of the mortality in our study sample; recent clinical trials have reported only a 0.5% therapy-related death rate among patients receiving FU therapy. 41 Furthermore, we found that duration of treatment was more strongly associated with colon cancer specific survival than with overall survival. This pattern reinforces the view that the duration of treatment is indeed contributing to a reduction in colon cancer mortality and does not represent merely selection bias. Most studies of treatment discontinuation have focused on oral medications, such as those for the treatment of HIV, 42 heart disease, 43,44 and psychiatric disorders. 45 In these settings, poor adherence accounts for worsening disease, death, and increased health care costs. 46,47 A decision to discontinue treatment may be based on such factors as the adverse effects of medications, 48 patient lack of knowledge about the illness or the potential benefits of the treatment, 49, JOURNAL OF CLINICAL ONCOLOGY
6 Adjuvant CT for Colon Cancer in the Elderly Variable Table 4. Mortality Hazard Ratios Among Patients Initiating FU and Surviving 8 Months Colon Cancer Specific Survival Hazard Ratio 95% CI Overall Survival Duration of treatment, months Referent 1.00 Referent to to 0.71 Age at diagnosis, years Referent 1.00 Referent to to to to to to 1.63 Race White 1.00 Referent 1.00 Referent Black to to 1.55 Sex Male 1.00 Referent 1.00 Referent Female to to 1.19 Marital status Unmarried 1.00 Referent 1.00 Referent Married to to 1.01 Positive lymph nodes Referent 1.00 Referent to to 2.20 Grade Well/moderately differentiated 1.00 Referent 1.00 Referent Poorly differentiated to to 1.96 Klabunde-Charlson comorbidity score Referent 1.00 Referent to to to to 2.03 Residence Metropolitan area 1.00 Referent 1.00 Referent Nonmetropolitan area to to 1.13 Hospital where diagnosed Nonteaching 1.00 Referent 1.00 Referent Teaching to to 1.16 Socioeconomic status Lowest quintile 1.00 Referent 1.00 Referent Second quintile to to 1.02 Third quintile to to 1.22 Fourth quintile to to 1.22 Highest quintile to to 1.19 Hazard Ratio Abbreviation: FU, fluorouracil. Based on Cox proportional hazards regression models in which each variable was adjusted for all others and year of diagnosis. 95% CI financial barriers, 30 poor patient-physician communication, 49,51 and the presence of comorbid conditions. 43,52,53 Personal belief in the efficacy of the therapy may also play a significant role in adherence. 54 Our analysis could take few of these factors into account and could not determine what roles patients, physicians, families, and the health care system played in determining the duration of treatment. However, in a Medicare population, at least some financial barriers are absent, and we used Medicare data to control for comorbid conditions, which were indeed statistically significant predictors of treatment and early and later mortality. Another limitation of our study was a lack of detailed information on chemotherapy dose and dose-intensity. Although dose reductions may contribute to suboptimal outcomes, especially among elderly patients, adjustment for dose is unlikely to account for the difference in survival between patients treated for 1 to 4 months and patients treated for 5 to 7 months. Our inability to take dose into account seems more likely to have biased our results toward the null than to account for the strong association we observed. New treatments for colorectal cancer are superseding the FUbased regimens, but although these agents appear to improve survival, they are also more toxic than the FU-based regimens. 55,56 Patients who receive these new chemotherapeutic agents may therefore be even more inclined than the patients we studied to discontinue treatment. For example, in a clinical trial, adding oxaliplatin to FU resulted in a lower likelihood of completing all cycles of chemotherapy (75% v 86%) and a reduced total dose of FU administered (84% v 98%). 41 Likewise, patients in a randomized trial of continuous-infusion FU were more likely to discontinue adjuvant therapy than those in the
7 Neugut et al Fig 2. (A) Kaplan-Meier colon cancer specific survival among patients who survived more than 8 months after diagnosis, by duration of treatment. (B) Kaplan-Meier overall survival among patients who survived more than 8 months after diagnosis, by duration of treatment. arm with bolus FU and leucovorin, due to the increased difficulties associated with administration. 35 Research is needed on ways to minimize the adverse effects of chemotherapeutic drugs and to facilitate adherence so that patients can receive in full whatever survival benefits the treatments can provide. Our study is the first to explore factors associated with the duration of adjuvant FU chemotherapy in patients with colon cancer. We found that more than 30% of patients were treated for only 1 to 4 months, and that such patients had poorer survival than those who received 5 to 7 months of treatment. We do not know whether these differences in duration of treatment accounted for the observed differences in survival or reflected factors for which we were unable to control. Additional investigation is warranted to determine whether dose-intensity, cumulative dose, or other factors related to receipt of full adjuvant treatment for colon cancer are associated with survival. REFERENCES 1. Polychemotherapy for early breast cancer: An overview of the randomised trials Early Breast Cancer Trialists Collaborative Group. Lancet 352: , Moertel CG, Fleming TR, Macdonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 122: , O Connell MJ, Laurie JA, Kahn M, et al: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16: , Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med 332: , Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330: , Hryniuk W: Re: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 91:1425, Budman DR, Berry DA, Cirrincione CT, et al: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer: The Cancer and Leukemia Group B. J Natl Cancer Inst 90: , Lyman GH, Dale DC, Crawford J: Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J Clin Oncol 21: , Bickell NA, McEvoy MD: Physicians reasons for failing to deliver effective breast cancer care: A framework for underuse. Med Care 41: , Hershman D, McBride R, Jacobson JS, et al: Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol 23: , Weir HK, Thun MJ, Hankey BF, et al: Annual report to the nation on the status of cancer, , featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95: , Boyle P, Leon ME: Epidemiology of colorectal cancer. Br Med Bull 64:1-25, Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics, CA Cancer J Clin 51:15-36, Hawk ET, Limburg PJ, Viner JL: Epidemiology and prevention of colorectal cancer. Surg Clin North Am 82: , Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 49:33-64, Efficacy of adjuvant fluorouracil and folinic acid in colon cancer: International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345: , Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345: , Sundararajan V, Grann VR, Jacobson JS, et al: Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: A population-based study. Cancer J 7: , Sundararajan V, Mitra N, Jacobson JS, et al: Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 136: , Schrag D, Cramer LD, Bach PB, et al: Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 93: , Engstrom PF, Benson AB III, Cohen A, et al: NCCN Colorectal Cancer Practice Guidelines: The National Comprehensive Cancer Network. Oncology (Huntingt) 10: , Potosky AL, Riley GF, Lubitz JD, et al: Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31: , Warren JL, Harlan LC, Fahey A, et al: Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 40:IV-55-61, 2002 (8 suppl) 24. Lamont EB, Lauderdale DS, Schilsky RL, et al: Construct validity of Medicare chemotherapy claims: The case of 5FU. Med Care 40: , Bach PB, Guadagnoli E, Schrag D, et al: Patient demographic and socioeconomic characteristics in the SEER-Medicare database: Applications and limitations. Med Care 40:IV-19-25, 2002 (8 suppl) 26. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40: , Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45: , Klabunde CN, Potosky AL, Legler JM, et al: Development of a comorbidity index using physician claims data. J Clin Epidemiol 53: , Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127: , Balkrishnan R: Predictors of medication adherence in the elderly. Clin Ther 20: , JOURNAL OF CLINICAL ONCOLOGY
8 Adjuvant CT for Colon Cancer in the Elderly 31. Stone VE, Hogan JW, Schuman P, et al: Antiretroviral regimen complexity, self-reported adherence, and HIV patients understanding of their regimens: Survey of women in the HER study. J Acquir Immune Defic Syndr 28: , Ahn JB, Shim KY, Jeung HC, et al: Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer. Cancer Lett 167: , Wolmark N, Rockette H, Fisher B, et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11: , O Connell MJ, Mailliard JA, Kahn MJ, et al: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15: , Poplin EA, Benedetti JK, Estes NC, et al: Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 23: , Chau I, Norman AR, Cunningham D, et al: A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 16: , Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10-15, Lyman GH, Dale DC, Friedberg J, et al: Incidence and predictors of low chemotherapy doseintensity in aggressive non-hodgkin s lymphoma: A nationwide study. J Clin Oncol 22: , Partridge AH, Wang PS, Winer EP, et al: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21: , Silliman RA, Guadagnoli E, Rakowski W, et al: Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer. J Clin Oncol 20: , Andre T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: , Murri R, Ammassari A, Trotta MP, et al: Patient-reported and physician-estimated adherence to HAART: Social and clinic center-related factors are associated with discordance. J Gen Intern Med 19: , Jackevicius CA, Mamdani M, Tu JV: Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288: , Waeber B, Leonetti G, Kolloch R, et al: Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens 17: , Misdrahi D, Llorca PM, Lancon C, et al: Compliance in schizophrenia: Predictive factors, therapeutical considerations and research implications. Encephale 28: , McDonnell PJ, Jacobs MR: Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 36: , Horwitz RI, Horwitz SM: Adherence to treatment and health outcomes. Arch Intern Med 153: , van Servellen G, Chang B, Garcia L, et al: Individual and system level factors associated with treatment nonadherence in human immunodeficiency virus-infected men and women. AIDS Patient Care STDS 16: , Lacro JP, Dunn LB, Dolder CR, et al: Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. J Clin Psychiatry 63: , Perkins DO: Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 63: , Okuno J, Yanagi H, Tomura S: Is cognitive impairment a risk factor for poor compliance among Japanese elderly in the community? Eur J Clin Pharmacol 57: , Cramer J, Rosenheck R, Kirk G, et al: Medication compliance feedback and monitoring in a clinical trial: Predictors and outcomes. Value Health 6: , Haynes RB, McDonald HP, Garg AX: Helping patients follow prescribed treatment: Clinical applications. JAMA 288: , Fink AK, Gurwitz J, Rakowski W, et al: Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22: , Allegra C, Sargent DJ: Adjuvant therapy for colon cancer: The pace quickens. N Engl J Med 352: , O Connell MJ: Current status of adjuvant therapy for colorectal cancer. Oncology (Huntingt) 18: , 2004 Acknowledgment We thank the Applied Research Branch, Division of Cancer Prevention and Population Science, National Cancer Institute; the Office of Information Services, the Office of Strategic Planning, HCFA; Information Management Services; and the Surveillance, Epidemiology, and End Results tumor registries in the creation of the SEER-Medicare database. Authors Disclosures of Potential Conflicts of Interest The authors indicated no potential conflicts of interest. Author Contributions Conception and design: Alfred I. Neugut, Matthew Matasar, Russell McBride, Judith S. Jacobson, Victor R. Grann, Dawn L. Hershman Financial support: Alfred I. Neugut, Dawn L. Hershman Collection and assembly of data: Matthew Matasar, Xiaoyan Wang, Russell McBride, Dawn L. Hershman Data analysis and interpretation: Alfred I. Neugut, Matthew Matasar, Xiaoyan Wang, Russell McBride, Judith S. Jacobson, Wei-Yann Tsai, Victor R. Grann, Dawn L. Hershman Manuscript writing: Alfred I. Neugut, Judith S. Jacobson, Dawn L. Hershman Final approval of manuscript: Alfred I. Neugut, Xiaoyan Wang, Russell McBride, Judith S. Jacobson, Wei-Yann Tsai, Victor R. Grann, Dawn L. Hershman
OVER the past three decades, numerous randomized
Journal of Gerontology: MEDICAL SCIENCES 2005, Vol. 60A, No. 9, 1137 1144 Copyright 2005 by The Gerontological Society of America Effectiveness of Adjuvant for Node-Positive Operable Breast Cancer in Older
More informationGastrointestinal Cancer
Gastrointestinal Cancer Referral to Medical Oncology: A Crucial Step in the Treatment of Older Patients with Stage III Colon Cancer RuiLi Luo, a,b Sharon H. Giordano, d Jean L. Freeman, a c Dong Zhang,
More informationTHE SURVIVAL BENEFITS OF
ORIGINAL INVESTIGATION Adjuvant Chemotherapy After Resection in Elderly Medicare and Medicaid Patients With Colon Cancer Cathy J. Bradley, PhD; Charles W. Given, PhD; Bassam Dahman, MS; Timothy L. Fitzgerald,
More informationAdjuvant Chemotherapy for Patients with Stage III Colon Cancer: Results from a CDC-NPCR Patterns of Care Study
COLON CANCER ORIGINAL RESEARCH Adjuvant Chemotherapy for Patients with Stage III Colon Cancer: Results from a CDC-NPCR Patterns of Care Study Rosemary D. Cress 1, Susan A. Sabatino 2, Xiao-Cheng Wu 3,
More informationFactors associated with delayed time to adjuvant chemotherapy in stage iii colon cancer
Curr Oncol, Vol. 21, pp. 181-186 doi: http://dx.doi.org/10.3747/co.21.1963 DELAYED TIME TO ADJUVANT CHEMOTHERAPY ORIGINAL ARTICLE Factors associated with delayed time to adjuvant chemotherapy in stage
More informationORIGINAL INVESTIGATION. Effect of a Dementia Diagnosis on Survival of Older Patients After a Diagnosis of Breast, Colon, or Prostate Cancer
ORIGINAL INVESTIGATION Effect of a Dementia Diagnosis on Survival of Older Patients After a Diagnosis of Breast, Colon, or Prostate Cancer Implications for Cancer Care Mukaila A. Raji, MD, MSc; Yong-Fang
More informationBreast Cancer Among the Oldest Old: Tumor Characteristics, Treatment Choices, and Survival
VOLUME 28 NUMBER 12 APRIL 20 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Breast Cancer Among the Oldest Old: Tumor Characteristics, Treatment Choices, and Survival Mara A. Schonberg,
More informationGSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAdjuvant therapies for large bowel cancer Wasantha Rathnayake, MD
LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant
More informationThe Linked SEER-Medicare Data and Cancer Effectiveness Research
The Linked SEER-Medicare Data and Cancer Effectiveness Research Arnold L. Potosky, PhD Professor of Oncology Director of Health Services Research Georgetown University Medical Center Lombardi Comprehensive
More informationNON-ADHERENCE TO ADJUVANT HORMONAL TREATMENT IN EARLY BREAST CANCER
NON-ADHERENCE TO ADJUVANT HORMONAL TREATMENT IN EARLY BREAST CANCER C. Volovat 1, C. Lupascu 2, Simona-Ruxandra Volovat 1, E. Zbranca 3 1. Center of Medical Oncology Iasi 2. I. Tanasescu Vl. Butureanu
More informationRelative dose intensity delivered to patients with early breast cancer: Canadian experience
M E D I C A L O N C O L O G Y Relative dose intensity delivered to patients with early breast cancer: Canadian experience S. Raza MD, S. Welch MD, and J. Younus MD ABSTRACT Adjuvant chemotherapy for early
More informationArecent randomized controlled trial (RCT) established
Neuro-Oncology 12(2):190 198, 2010. doi:10.1093/neuonc/nop004 NEURO-ONCOLOGY The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme Rose Lai, Dawn L. Hershman,
More informationOriginal article. Introduction. Patients and methods
Original article Annals of Oncology 16: 767 772, 2005 doi:10.1093/annonc/mdi159 Published online 7 April 2005 Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands
More informationTHE IMPORTANCE OF COMORBIDITY TO CANCER CARE AND STATISTICS AMERICAN CANCER SOCIETY PRESENTATION COPYRIGHT NOTICE
THE IMPORTANCE OF COMORBIDITY TO CANCER CARE AND STATISTICS AMERICAN CANCER SOCIETY PRESENTATION COPYRIGHT NOTICE Washington University grants permission to use and reproduce the The Importance of Comorbidity
More informationTreatment disparities for patients diagnosed with metastatic bladder cancer in California
Treatment disparities for patients diagnosed with metastatic bladder cancer in California Rosemary D. Cress, Dr. PH, Amy Klapheke, MPH Public Health Institute Cancer Registry of Greater California Introduction
More informationThe American Cancer Society estimates that there will be
ORIGINAL ARTICLE Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,* David M. Kent, MD, MS, and Gary M.
More informationStage III Colon Cancer Susquehanna Cancer Center Warren L Robinson, MD, FACP May 9, 2007
Stage III Colon Cancer Susquehanna Cancer Center 1997-21 Warren L Robinson, MD, FACP May 9, 27 Stage III Colon Cancer Susquehanna Cancer Center 1997-21 Colorectal cancer is the third most common cancer
More informationComparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes B Versus Dukes C Colon Cancer: Results From
Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes B Versus Dukes C Colon Cancer: Results From Four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03,
More informationCurrent Status of Adjuvant Therapy for Colorectal Cancer
Review Article [1] May 01, 2004 By Michael J. O connell, MD [2] Adjuvant therapy with chemotherapy and/or radiation therapy in addition to surgery improves outcome for patients with high-risk carcinomas
More informationEfficiency and tolerability of 5- fluorouracil-based adjuvant chemotherapy in elderly patients with colorectal carcinoma
Turkish Journal of Cancer Volume 34, No.4, 2004 139 Efficiency and tolerability of 5- fluorouracil-based adjuvant chemotherapy in elderly patients with colorectal carcinoma LHAN ÖZTOP 1, ARZU YAREN 1,
More informationDAYS IN PANCREATIC CANCER
HOSPITAL AND MEDICAL CARE DAYS IN PANCREATIC CANCER Annals of Surgical Oncology, March 27, 2012 Casey B. Duncan, Kristin M. Sheffield, Daniel W. Branch, Yimei Han, Yong-Fang g Kuo, James S. Goodwin, Taylor
More informationAdjuvant chemotherapy outcomes in patients over 65 years with early stage colorectal carcinoma
JBUON 2014; 19(4): 906-912 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Adjuvant chemotherapy outcomes in patients over 65 years with early
More information6/20/2012. Co-authors. Background. Sociodemographic Predictors of Non-Receipt of Guidelines-Concordant Chemotherapy. Age 70 Years
Sociodemographic Predictors of Non-Receipt of Guidelines-Concordant Chemotherapy - among Locoregional Breast Cancer Patients Under Age 70 Years Xiao-Cheng Wu, MD, MPH 2012 NAACCR Annual Conference June
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationAttendance rates and outcomes of cardiac rehabilitation in Victoria, 1998
Attendance rates and outcomes of cardiac rehabilitation in Victoria, 1998 CARDIOVASCULAR DISEASE is the leading cause of death in Australia, causing more than 40% of all deaths in 1998. 1 Cardiac rehabilitation
More informationTHE RESULTS OF A NATIONAL INstitutes
ORIGINAL CONTRIBUTION Adjuvant Chemotherapy for Stage III Colon Cancer Implications of Race/Ethnicity, Age, and Differentiation J. Milburn Jessup, MD Andrew Stewart, MS Frederick L. Greene, MD Bruce D.
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationComparative Study on Three Algorithms of the ICD-10 Charlson Comorbidity Index with Myocardial Infarction Patients
Journal of Preventive Medicine and Public Health January 2010, Vol. 43, No. 1, 42-49 doi: 10.3961/jpmph.2010.43.1.42 Comparative Study on Three Algorithms of the ICD-10 Charlson Comorbidity Index with
More informationSUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.
Supplementary Figure S1. Cohort definition flow chart. Supplementary Table S1. Baseline characteristics of study population grouped according to having developed incident CKD during the follow-up or not
More informationTHE SURVIVORSHIP EXPERIENCE IN PANCREATIC CANCER
THE SURVIVORSHIP EXPERIENCE IN PANCREATIC CANCER Casey A. Boyd, Jaime Benarroch, Kristin M. Sheffield, Yimei Han, Catherine D. Cooksley, Taylor S. Riall Department of Surgery The University of Texas Medical
More informationBreast cancer, diagnosed in 180,000 women in the United
Delayed Radiotherapy for Breast Cancer Patients in Integrated Delivery Systems Heather Taffet Gold, PhD; Soe Soe Thwin, PhD; Diana S. M. Buist, PhD, MPH; Terry S. Field, DSc; Feifei Wei, PhD; Marianne
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationUsing claims data to investigate RT use at the end of life. B. Ashleigh Guadagnolo, MD, MPH Associate Professor M.D. Anderson Cancer Center
Using claims data to investigate RT use at the end of life B. Ashleigh Guadagnolo, MD, MPH Associate Professor M.D. Anderson Cancer Center Background 25% of Medicare budget spent on the last year of life.
More informationPhysician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer
Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown,
More informationSurveillance of Pancreatic Cancer Patients Following Surgical Resection
Surveillance of Pancreatic Cancer Patients Following Surgical Resection Jaime Benarroch-Gampel, M.D., M.S. CERCIT Scholar CERCIT Workshops March 16, 2012 INTRODUCTION Pancreatic cancer is the 4 th leading
More informationDepression is associated with impaired recovery from a
Effect of Depression on Diagnosis, Treatment, and Survival of Older Women with Breast Cancer James S. Goodwin, MD, Dong D. Zhang, PhD, and Glenn V. Ostir, PhD OBJECTIVES: To assess the effect of a prior
More informationA DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY. Helen Mari Parsons
A Culture of Quality? Lymph Node Evaluation for Colon Cancer Care A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY Helen Mari Parsons IN PARTIAL FULFILLMENT
More informationManagement of Advanced Colorectal Cancer in Older Patients
Review Article [1] April 15, 2005 By Stuart M. Lichtman, MD, FACP [2] Many elderly individuals have substantial life expectancy, even in the setting of significant illness. There is evidence to indicate
More informationEfficacy and Toxicity of Adjuvant Chemotherapy in Elderly Patients with Colon Carcinoma
1931 Efficacy and Toxicity of Adjuvant Chemotherapy in Elderly Patients with Colon Carcinoma A 10-Year Experience of the Geisinger Medical Center Farid Fata, M.D. 1 Ayoub Mirza, M.D. 2 G. Craig Wood, M.S.
More informationSurvival Difference between Non-Hispanic Black and Non-Hispanic White Women with Localized Breast Cancer: The Impact of Guideline-Concordant Therapy
o r i g i n a l c o m m u n i c a t i o n Survival Difference between Non-Hispanic Black and Non-Hispanic White Women with Localized Breast Cancer: The Impact of Guideline-Concordant Therapy Xiaocheng
More informationEffectiveness of Radiation Therapy for Older Women With Early Breast Cancer
Effectiveness of Therapy for Older Women With Early Breast Cancer Benjamin D. Smith, Cary P. Gross, Grace L. Smith, Deron H. Galusha, Justin E. Bekelman, Bruce G. Haffty Background: Recent clinical trials
More informationHospital Lymph Node Examination Rates and Survival After Resection for Colon Cancer
ORIGINAL CONTRIBUTION Hospital Lymph Node Examination Rates and Survival After Resection for Colon Cancer Sandra L. Wong, MD, MS Hong Ji, MS Brent K. Hollenbeck, MD, MS Arden M. Morris, MD, MPH Onur Baser,
More informationComparison of Medicare Fee-for-Service Beneficiaries Treated in Ambulatory Surgical Centers and Hospital Outpatient Departments
Comparison of Medicare Fee-for-Service Beneficiaries Treated in Ambulatory Surgical Centers and Hospital Outpatient Departments Prepared for: American Hospital Association April 4, 2019 Berna Demiralp,
More informationTheresa Keegan, Ph.D., M.S. Associate Professor Department of Internal Medicine Division of Hematology and Oncology
Impact of treatment and insurance on socioeconomic disparities in survival after adolescent and young adult Hodgkin lymphoma: A population- based study Theresa Keegan, Ph.D., M.S. Associate Professor Department
More informationRetrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal patients in the adjuvant setting
ORIGINAL ARTICLE CAPOX AND mfolfox6 DOSE INTENSITY AND CLINICAL OUTCOMES IN STAGE III CRC, Mamo et al. Retrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal
More informationToxicities of Chemotherapy Regimens used in Early Breast Cancer
Toxicities of Chemotherapy Regimens used in Early Breast Cancer CERCIT Workshop February 17, 2012 Carlos H Barcenas, M.D., M.S. Fellow Hematology-Oncology MD Anderson Cancer Center CERCIT Scholar Outline
More informationTHE VALIDITY OF ADMINISTRATIVE DATA AND PATTERNS OF CHEMOTHERAPY USE AMONG ELDERLY COLORECTAL CANCER PATIENTS. Jennifer L.
THE VALIDITY OF ADMINISTRATIVE DATA AND PATTERNS OF CHEMOTHERAPY USE AMONG ELDERLY COLORECTAL CANCER PATIENTS Jennifer L. Lund, MSPH A dissertation submitted to the faculty of the University of North Carolina
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More informationBLACK MEDICAID BENEFICIARIES EXPERIENCE BREAST CANCER TREATMENT DELAYS MORE FREQUENTLY THAN WHITES
BLACK MEDICAID BENEFICIARIES EXPERIENCE BREAST CANCER TREATMENT DELAYS MORE FREQUENTLY THAN WHITES Objective: Delays in treatment initiation may contribute to the poorer breast cancer survival among Black
More informationRisk of Fractures Following Cataract Surgery in Medicare Beneficiaries
Risk of Fractures Following Cataract Surgery in Medicare Beneficiaries Victoria L. Tseng, MD, Fei Yu, PhD, Flora Lum, MD, Anne L. Coleman, MD, PhD JAMA. 2012;308(5):493-501 Background Visual impairment
More informationMETHODS RESULTS. Supported by funding from Ortho-McNeil Janssen Scientific Affairs, LLC
PREDICTORS OF MEDICATION ADHERENCE AMONG PATIENTS WITH SCHIZOPHRENIC DISORDERS TREATED WITH TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN A LARGE STATE MEDICAID PROGRAM S.P. Lee 1 ; K. Lang 2 ; J. Jackel 2 ;
More informationFinancial Disclosure. Learning Objectives. Review and Impact of the NCDB PUF. Moderator: Sandra Wong, MD, MS, FACS, FASCO
Review and Impact of the NCDB PUF Moderator: Sandra Wong, MD, MS, FACS, FASCO Financial Disclosure I do not have personal financial relationships with any commercial interests Learning Objectives At the
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life
More informationRacial Disparities and Survival for Nonsmall-Cell Lung Cancer in a Large Cohort of Black and White Elderly Patients
Racial Disparities and Survival for Nonsmall-Cell Lung Cancer in a Large Cohort of Black and White Elderly Patients Dale Hardy, PhD 1 ; Rui Xia, MS 1 ; Chih-Chin Liu, MS 1 ; Janice N. Cormier, MD, MPH
More informationThe role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy
The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationThe Influence of Comorbidities on Overall Survival Among Older Women Diagnosed With Breast Cancer
DOI: 10.1093/jnci/djr188 Advance Access publication on June 30, 2011. The Author 2011. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
More informationThe Use of Clinical Trial Data in Combination with External Data Sources to Examine Novel Cancer Research Questions: A Modified Big Data Approach
The Use of Clinical Trial Data in Combination with External Data Sources to Examine Novel Cancer Research Questions: A Modified Big Data Approach Joseph Unger, Ph.D. Assistant Member, Public Health Sciences
More informationCorrelations of Obesity, Comorbidity and Treatment: Implications for Survival Analysis and Interpretation
Correlations of Obesity, Comorbidity and Treatment: Implications for Survival Analysis and Interpretation Rachel Ballard-Barbash, MD, MPH Applied Research Program (ARP) Division of Cancer Control and Population
More informationClinical and Economic Outcomes Associated with Adjuvant Chemotherapy in Elderly Patients with Early Stage Operable Breast Cancer
VALUE IN HEALTH 15 (2012) 72 80 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/jval Clinical and Economic Outcomes Associated with Adjuvant Chemotherapy in Elderly
More informationImpact of Adjuvant Chemotherapy in Patients With Curatively Resected Stage IV Colorectal Cancer
Impact of in Patients With Curatively Resected Stage IV Colorectal Cancer Hirotoshi Kobayashi, MD, FACS, Kenjiro Kotake, MD, and Kenichi Sugihara, MD, Study Group for Peritoneal Metastasis from Colorectal
More informationVariation in Modes of Chemotherapy Administration for Breast Carcinoma and Association with Hospitalization for Chemotherapy-Related Toxicity
913 Variation in Modes of Chemotherapy Administration for Breast Carcinoma and Association with Hospitalization for Chemotherapy-Related Toxicity Xianglin L. Du, M.D., Ph.D. 1 Wenyaw Chan, Ph.D. 2 Sharon
More informationRates and patterns of participation in cardiac rehabilitation in Victoria
Rates and patterns of participation in cardiac rehabilitation in Victoria Vijaya Sundararajan, MD, MPH, Stephen Begg, MS, Michael Ackland, MBBS, MPH, FAPHM, Ric Marshall, PhD Victorian Department of Human
More informationadherence research Introduction Breast cancer is the most common cancer diagnosis among women in the United States,
Psychosocial factors in adjuvant hormone therapy for breast cancer: An emerging context for adherence research Introduction Breast cancer is the most common cancer diagnosis among women in the United States,
More informationUse of Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer in the United States
International Journal of Radiation Oncology biology physics www.redjournal.org Clinical Investigation: Thoracic Cancer Use of Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer
More informationQuality Indicators of Laryngeal Cancer Care in the Elderly
The Laryngoscope VC 2014 The American Laryngological, Rhinological and Otological Society, Inc. Quality Indicators of Laryngeal Cancer Care in the Elderly Christine G. Gourin, MD, MPH; Kevin D. Frick,
More informationRetention of Enrollees Following a Cancer Diagnosis Within Health Maintenance Organizations in the Cancer Research Network
Retention of Enrollees Following a Cancer Diagnosis Within Health Maintenance Organizations in the Cancer Research Network Terry S. Field, Jackie Cernieux, Diana Buist, Ann Geiger, Lois Lamerato, Gene
More informationDATA ELEMENTS NEEDED FOR QUALITY ASSESSMENT COPYRIGHT NOTICE
DATA ELEMENTS NEEDED FOR QUALITY ASSESSMENT COPYRIGHT NOTICE Washington University grants permission to use and reproduce the Data Elements Needed for Quality Assessment exactly as it appears in the PDF
More informationNorthwestern University, Division of Hematology/Oncology, Chicago, Illinois, USA. Key Words. Colon cancer Stage II Adjuvant chemotherapy
The Oncologist Dialogues in Oncology Adjuvant Therapy in Stage II Colon Cancer: Current Approaches LISA BADDI, AL BENSON III Northwestern University, Division of Hematology/Oncology, Chicago, Illinois,
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationFinancial Disclosure. Team. Race-based Socioeconomic and Treatment Disparities in Adolescents and Young Adults with Stage II-III Rectal Cancer
Race-based Socioeconomic and Treatment Disparities in Adolescents and Young Adults with Stage II-III Rectal Cancer Melanie Goldfarb MD, MSc, FACS, FACE John Wayne Cancer Institute at PSJHC, Santa Monica,
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/24307 holds various files of this Leiden University dissertation Author: Broek, Colette van den Title: Optimisation of colorectal cancer treatment Issue
More informationTrends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma
Trends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma Taylor S. Riall, MD, PhD CERCIT Workshop October 19, 2012 Department of Surgery Center for Comparative Effectiveness
More informationAnkle fractures are one of
Elevated Risks of Ankle Fracture Surgery in Patients With Diabetes Nelson F. SooHoo, MD, Lucie Krenek, MD, Michael Eagan, MD, and David S. Zingmond, MD, PhD Ankle fractures are one of the most common types
More informationDoes Reimbursement Influence Chemotherapy Treatment for Cancer Patients?
Does Reimbursement Influence Chemotherapy Treatment for Cancer Patients? Mireille Jacobson, A. James O Malley, Craig C. Earle, Juliana Pakes, Peter Gaccione, Joseph P. Newhouse Mireille Jacobson (contact
More informationComparative Effectiveness of Adjuvant Chemotherapy in Elderly Colon Cancer Patients
Cancer and Clinical Oncology; Vol. 2, No. 1; 2013 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Comparative Effectiveness of Adjuvant Chemotherapy in Elderly Colon
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationSTUDY. The Association of Medicare Health Care Delivery Systems With Stage at Diagnosis and Survival for Patients With Melanoma
STUDY The Association of Medicare Health Care Delivery Systems With Stage at Diagnosis and Survival for Patients With Melanoma Robert S. Kirsner, MD, PhD; James D. Wilkinson, MD, MPH; Fangchao Ma, MD,
More informationAdjuvant Chemotherapy for Elderly Women with Breast Cancer: Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland
SIOG Berlin October 2009 Adjuvant Chemotherapy for Elderly Women with Breast Cancer: Immediate Benefit and Long-Term Risk Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland 1 2 BACKGROUND MESSAGE
More informationColon cancer is the third most common malignant neoplasm
n clinical n Post-treatment Surveillance in a Large Cohort of Patients With Colon Cancer Chung-Yuan Hu, PhD; George L. Delclos, MD, PhD; Wenyaw Chan, PhD; and Xianglin L. Du, MD, PhD Managed Care & Healthcare
More informationAndrogen deprivation therapy for treatment of localized prostate cancer and risk of
Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies Lauren P. Wallner, Renyi Wang, Steven J. Jacobsen, Reina Haque Department of Research and
More informationEndoscopic ultrasound and impact on survival in rectal cancer patients : a SEER-Medicare study.
Oregon Health & Science University OHSU Digital Commons Scholar Archive October 2010 Endoscopic ultrasound and impact on survival in rectal cancer patients : a SEER-Medicare study. Steven McNamara Follow
More informationDisclosure. Learning Objectives 6/4/2014. Medication Adherence: Challenges and Opportunities
Medication Adherence: Challenges and Opportunities Jessica W. Skelley, Pharm D., BCACP Assistant Professor of Pharmacy Practice McWhorter School of Pharmacy, Samford University jmwhalen@samford.edu Disclosure
More informationBringing the Fight to Cancer Annual Report
Bringing the Fight to Cancer. 216 Annual Report Quality Study Adherence to Adjuvant System Therapy Following Primary Surgery in Stage II Breast Cancer Patients: Baylor Scott & White Medical Center Irving
More informationSummary BREAST CANCER - Early Stage Breast Cancer... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 BREAST CANCER - Early Stage Breast Cancer... 3 Large data analysis reveals similar survival outcomes with sequential
More informationAge and factors associated with access and time to postoperative adjuvant chemotherapy in colon cancer: a French epidemiological study
Original Article Age and factors associated with access and time to postoperative adjuvant chemotherapy in colon cancer: a French epidemiological study Jean Capsec 1, Carole Lefebvre 1, Fabienne Chupé
More informationManagement of Malignant Colonic Polyps: A Population-Based Analysis of Colonoscopic Polypectomy Versus Surgery
Original Article Management of Malignant Colonic Polyps: A Population-Based Analysis of Colonoscopic Polypectomy Versus Surgery Gregory S. Cooper, MD 1,2 ; Fang Xu, MS 1,3 ; Jill S. Barnholtz Sloan, PhD
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationTreatment disparities among elderly colon cancer patients in the United States using SEER-Medicare data
Oregon Health & Science University OHSU Digital Commons Scholar Archive December 2009 Treatment disparities among elderly colon cancer patients in the United States using SEER-Medicare data Kelsea Shoop
More informationUse of Adjuvant Radiotherapy at Hospitals With and Without On-site Radiation Services
796 Use of Adjuvant Radiotherapy at With and Without On-site Radiation Services Sandra L. Wong, MD Yongliang Wei, MS John D. Birkmeyer, MD Michigan Surgical Collaborative for Outcomes Research and Evaluation,
More informationAward Number: W81XWH TITLE: "Racial Disparities in Palliative Care for Prostate Cancer." PRINCIPAL INVESTIGATOR: Alfred I.
Award Number: W81XWH-10-1-0802 TITLE: "Racial Disparities in Palliative Care for Prostate Cancer." PRINCIPAL INVESTIGATOR: Alfred I. Neugut, MD, PhD CONTRACTING ORGANIZATION: Columbia University New York,
More informationPredictors of Palliative Therapy Receipt in Stage IV Colorectal Cancer
Predictors of Palliative Therapy Receipt in Stage IV Colorectal Cancer Osayande Osagiede, MBBS, MPH 1,2, Aaron C. Spaulding, PhD 2, Ryan D. Frank, MS 3, Amit Merchea, MD 1, Dorin Colibaseanu, MD 1 ACS
More informationSurgeon Characteristics and Receipt of Adjuvant Radiotherapy in Women With Breast Cancer
ARTICLE Surgeon Characteristics and Receipt of Adjuvant Radiotherapy in Women With Breast Cancer Dawn L. Hershman, Donna Buono, Russell B. McBride, Wei Yann Tsai, Kathy Ann Joseph, Victor R. Grann, Judith
More informationAdjuvant therapy in older adults: controversies and challenges - Colorectal cancer -
International Society of Geriatric Oncology Lisbon October 23 rd 25t h 2014 Adjuvant therapy in older adults: controversies and challenges - Colorectal cancer - Claus-Henning Köhne Klinik für Onkologie
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationIdentifying Geographic & Socioeconomic Disparities in Access to Care for Pediatric Cancer Patients in Texas
Identifying Geographic & Socioeconomic Disparities in Access to Care for Pediatric Cancer Patients in Texas Mary T. Austin, MD, MPH Assistant Professor, Pediatric Surgery University of Texas Health Science
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationThe Pennsylvania State University. The Graduate School. Department of Public Health Sciences
The Pennsylvania State University The Graduate School Department of Public Health Sciences THE LENGTH OF STAY AND READMISSIONS IN MASTECTOMY PATIENTS A Thesis in Public Health Sciences by Susie Sun 2015
More informationBLACK-WHITE DIFFERENCES IN SURVIVAL FROM LATE-STAGE PROSTATE CANCER
BLACK-WHITE DIFFERENCES IN SURVIVAL FROM LATE-STAGE PROSTATE CANCER Objective: To examine differences between African Americans (Blacks) and non-hispanic Whites in risk of death after diagnosis of laterstage
More information